Literature DB >> 19384543

[Nobel price for vaccination against cervical cancer: current data and guidelines].

H M Hepburn1, A M Kaufmann.   

Abstract

Harald zur Hausen received the Nobel price for Medicine in 2008 for his seminal research on human papilloma viruses and their association with anogenital diseases. On the basis of his work highly effective prophylactic vaccines have been developed. Clinical studies have shown nearly 100% seroconversion and an excellent safety profile as well as greater than 96% efficacy against HPV infection and premalignant dysplasia, induced by HPV types covered by the vaccine. Due to the convincing data of phase II and III clinical trials the introduction of HPV vaccination was recommended by health authorities and scientific committees in Germany. The development and availability of guidelines and evidence-based recommendations should support the introduction of the vaccine and widespread vaccination.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19384543     DOI： 10.1007/s00108-009-2388-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  30 in total

1.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Authors:  Luisa L Villa; Kevin A Ault; Anna R Giuliano; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Darron R Brown; Alex Ferenczy; Diane M Harper; Laura A Koutsky; Robert J Kurman; Matti Lehtinen; Christian Malm; Sven-Eric Olsson; Brigitte M Ronnett; Finn Egil Skjeldestad; Margareta Steinwall; Mark H Stoler; Cosette M Wheeler; Frank J Taddeo; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Rocio Marchese; Mark T Esser; Janine Bryan; Kathrin U Jansen; Heather L Sings; Gretchen M Tamms; Alfred J Saah; Eliav Barr
Journal:  Vaccine       Date:  2006-05-15       Impact factor: 3.641

2.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

3.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

4.  Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.

Authors:  Cosette M Wheeler; Oliver M Bautista; Joanne E Tomassini; Margaret Nelson; Carlos A Sattler; Eliav Barr
Journal:  Vaccine       Date:  2007-12-05       Impact factor: 3.641

5.  Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

Authors:  Keith S Reisinger; Stan L Block; Eduardo Lazcano-Ponce; Rudiwilai Samakoses; Mark T Esser; Joanne Erick; Derek Puchalski; Katherine E D Giacoletti; Heather L Sings; Suzanne Lukac; Frances B Alvarez; Eliav Barr
Journal:  Pediatr Infect Dis J       Date:  2007-03       Impact factor: 2.129

6.  Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution.

Authors:  F P Booy; R B Roden; H L Greenstone; J T Schiller; B L Trus
Journal:  J Mol Biol       Date:  1998-08-07       Impact factor: 5.469

7.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

8.  Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.

Authors:  Suzanne M Garland; Marc Steben; Mauricio Hernandez-Avila; Laura A Koutsky; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Mark T Esser; Scott C Vuocolo; Micki Nelson; Radha Railkar; Carlos Sattler; Eliav Barr
Journal:  Clin Vaccine Immunol       Date:  2007-04-11

9.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.

Authors:  Kevin A Ault
Journal:  Lancet       Date:  2007-06-02       Impact factor: 79.321

10.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Authors:  L L Villa; R L R Costa; C A Petta; R P Andrade; J Paavonen; O-E Iversen; S-E Olsson; J Høye; M Steinwall; G Riis-Johannessen; A Andersson-Ellstrom; K Elfgren; G von Krogh; M Lehtinen; C Malm; G M Tamms; K Giacoletti; L Lupinacci; R Railkar; F J Taddeo; J Bryan; M T Esser; H L Sings; A J Saah; E Barr
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640
View more
  1 in total

Review 1.  [Prophylactic and therapeutic vaccines against human papilloma virus].

Authors:  A E Albers; T K Hoffmann; J P Klussmann; A M Kaufmann
Journal:  HNO       Date:  2010-08       Impact factor: 1.284
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.